Reoxygenation using a novel CO2 therapy decreases the metastatic potential of osteosarcoma cells

Experimental Cell Research

Volumn 319, Issue 13, 2013, Pages 1988-1997

  Harada, Risa ^a   Kawamoto, Teruya ^a   Ueha, Takeshi ^b   Minoda, Masaya ^a   Toda, Mitsunori ^a   Onishi, Yasuo ^a   Fukase, Naomasa ^a   Hara, Hitomi ^a   Sakai, Yoshitada ^a   Miwa, Masahiko ^a   Kuroda, Ryosuke ^a   Kurosaka, Masahiro ^a   Akisue, Toshihiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NeoChemir Inc   (Japan)

Author keywords

Hypoxia; Matrix metalloproteinase (MMP); Metastasis; Osteosarcoma

Indexed keywords

CARBON DIOXIDE; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; HYPOXEMIA; HYPOXIA; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOXYGENATION; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; DRUG EFFECT; DRUG SCREENING; HUMAN; INTRADERMAL DRUG ADMINISTRATION; LUNG TUMOR; MATRIX METALLOPROTEINASE (MMP); METASTASIS; NUDE MOUSE; OXYGEN CONSUMPTION; PATHOLOGY; TRANSCUTANEOUS CO(2) APPLICATION; TUMOR CELL LINE;

HYPOXIA; MATRIX METALLOPROTEINASE (MMP); METASTASIS; OSTEOSARCOMA; TRANSCUTANEOUS CO(2) APPLICATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; BONE NEOPLASMS; CARBON DIOXIDE; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; OSTEOSARCOMA; OXYGEN CONSUMPTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879885976     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.05.019     Document Type: Article

References (43)

1. Ferguson W.S., Goorin A.M. Current treatment of osteosarcoma. Cancer Invest. 2001, 19:292-315.
2. Allison D.C., Carney S.C., Ahlmann E.R., Hendifar A., Chawla S., Fedenko A., Angeles C., Menendez L.R. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 2012:704872.
3. Longhi A., Errani C., De Paolis M., Mercuri M., Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat. Rev. 2006, 32:423-436.
4. Ta H.T., Dass C.R., Choong P.F., Dunstan D.E. Osteosarcoma treatment: state of the art. Cancer Metast. Rev. 2009, 28:247-263.
5. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-4515.
6. Vaupel P., Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9(Suppl 5):4-9.
7. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Nat. Cancer Inst. 2001, 93:266-276.
8. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
9. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
10. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metast. Rev. 2007, 26:225-239.
11. Miyazawa M., Yasuda M., Fujita M., Hirasawa T., Kajiwara H., Hirabayashi K., Ogane N., Shimizu M., Asanuma H., Murakami M., Takekoshi S., Mikami M., Osamura R.Y. Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Arch. Gynecol. Obstet. 2009, 279:789-796.
12. Zeng W., Wan R., Zheng Y., Singh S.R., Wei Y. Hypoxia, stem cells and bone tumor. Cancer Lett. 2011, 313:129-136.
13. Jing S.W., Wang Y.D., Chen L.Q., Sang M.X., Zheng M.M., Shun G.G., Liu Q., Cheng Y.J., Yang C.R. Hypoxia suppresses E-cadherin and enhances matrix metalloproteinase-2 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor-1 alpha activation. Dis. Esophagus 2013, 26:75-83.
14. Guruvayoorappan C., Kuttan G. Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacol. Immunotoxicol. 2008, 30:711-727.
15. Waas E.T., Wobbes T., Lomme R.M., DeGroot J., Ruers T., Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br. J. Surg. 2003, 90:1556-1564.
16. Liao C.L., Lai K.C., Huang A.C., Yang J.S., Lin J.J., Wu S.H., Gibson W.W., Lin J.G., Chung J.G. Gallic acid inhibits migration and invasion in human osteosarcoma U-2 OS cells through suppressing the matrix metalloproteinase-2/-9, protein kinase B (PKB) and PKC signaling pathways. Food Chem. Toxicol. 2012, 50:1734-1740.
17. Sakai Y., Miwa M., Oe K., Ueha T., Koh A., Niikura T., Iwakura T., Lee S.Y., Tanaka M., Kurosaka M. A novel system for transcutaneous application of carbon dioxide causing an artificial Bohr effect in the human body. PLoS One 2011, 6:e24137.
18. Oe K., Ueha T., Sakai Y., Niikura T., Lee S.Y., Koh A., Hasegawa T., Tanaka M., Miwa M., Kurosaka M. The effect of transcutaneous application of carbon dioxide (CO(2)) on skeletal muscle. Biochem. Biophys. Res. Commun. 2011, 407:148-152.
19. 2) enhances chemosensitivity by reducing hypoxic conditions in human malignant fibrous histiocytoma. J. Cancer Sci. Ther. 2012, 4:174-181.
20. 2) induces mitochondrial apoptosis in human malignant fibrous histiocytoma in vivo. PLoS One 2012, 7:e49189.
21. Okada Y., Akisue T., Hara H., Kishimoto K., Kawamoto T., Imabori M., Kishimoto S., Fukase N., Onishi Y., Kurosaka M. The effect of bevacizumab on tumour growth of malignant fibrous histiocytoma in an animal model. Anticancer Res. 2010, 30:3391-3395.
22. Niinaka Y., Harada K., Fujimuro M., Oda M., Haga A., Hosoki M., Uzawa N., Arai N., Yamaguchi S., Yamashiro M., Raz A. Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res. 2010, 70:9483-9493.
23. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
24. Kager L., Zoubek A., Potschger U., Kastner U., Flege S., Kempf-Bielack B., Branscheid D., Kotz R., Salzer-Kuntschik M., Winkelmann W., Jundt G., Kabisch H., Reichardt P., Jurgens H., Gadner H. S.S. Bielack and the Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J. Clin. Oncol. 2003, 21:2011-2018.
25. Yui Y., Itoh K., Yoshioka K., Naka N., Watanabe M., Hiraumi Y., Matsubara H., Watanabe K., Sano K., Nakahata T., Adachi S. Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8. Clin. Exp. Metastas. 2010, 27:619-630.
26. Kamei S., Sakayama K., Tamashiro S., Aizawa J., Miyawaki J., Miyazaki T., Yamamoto H., Norimatsu Y., Masuno H. Ketoprofen in topical formulation decreases the matrix metalloproteinase-2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma. J. Orthop. Res. 2009, 27:909-915.
27. Hockel M., Schlenger K., Mitze M., Schaffer U., Vaupel P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 1996, 6:3-9.
28. Yang Q.C., Zeng B.F., Dong Y., Shi Z.M., Jiang Z.M., Huang J. Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn. J. Clin. Oncol. 2007, 37:127-134.
29. Semenza G.L. Life with oxygen. Science 2007, 318:62-64.
30. Wu X.Y., Fu Z.X., Wang X.H. Effect of hypoxia-inducible factor 1-alpha on Survivin in colorectal cancer. Mol. Med. Rep. 2010, 3:409-415.
31. S. Shah, Hypoxia in tumor angiogenesis and metastasis: evaluation of VEGF and MMP over-expression and down-regulation of HIF-1a with RNAi in hypoxic tumor cells, Pharmaceutical Science Master's Theses 18, 2010.
32. Shyu K.G., Hsu F.L., Wang M.J., Wang B.W., Lin S. Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion. Exp. Cell Res. 2007, 313:1181-1191.
33. Gullu I.H., Kurdoglu M., Akalin I. The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer. Br. J. Cancer 2000, 82:249.
34. Mizutani K., Kofuji K., Shirouzu K. The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer. Surg. Today 2000, 30:614-621.
35. Mendes O., Kim H.T., Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin. Exp. Metastas. 2005, 22:237-246.
36. Trudel D., Fradet Y., Meyer F., Harel F., Tetu B. Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry. Hum. Pathol. 2008, 39:731-739.
37. Bjornland K., Flatmark K., Pettersen S., Aaasen A.O., Fodstad O., Maelandsmo G.M. Matrix metalloproteinases participate in osteosarcoma invasion. J. Surg. Res. 2005, 127:151-156.
38. Teicher B.A. Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy. Artif. Cell Blood Sub. 1994, 22:1109-1120.
39. Kawasoe Y., Yokouchi M., Ueno Y., Iwaya H., Yoshida H., Komiya S. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of osteosarcoma. Oncol. Rep. 2009, 22:1045-1050.
40. Kaanders J.H., Bussink J., van der Kogel A.J. Clinical studies of hypoxia modification in radiotherapy. Semin. Radiat. Oncol. 2004, 14:233-240.
41. Asai T., Ueda T., Itoh K., Yoshioka K., Aoki Y., Mori S., Yoshikawa H. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int. J. Cancer 1998, 76:418-422.
42. Zhang D., Pan X., Ohno S., Osuga T., Sawada S., Sato K. No effects of pulsed electromagnetic fields on expression of cell adhesion molecules (integrin, CD44) and matrix metalloproteinase-2/9 in osteosarcoma cell lines. Bioelectromagnetics 2011, 32:463-473.
43. Kuzmanov A., Wielockx B., Rezaei M., Kettelhake A., Breier G. Overexpression of factor inhibiting HIF-1 enhances vessel maturation and tumor growth via platelet-derived growth factor-C. Int. J. Cancer 2012, 131:E603-613.